Biochemical Engineering Special Interest Group
biological engineering professionals
18 October 2017

Kite and Gilead break into CAR-T market with early axi-cel nod

The FDA has approved Kite’s CAR-T, axicabtagene ciloleucel (axi-cel), about six weeks earlier than expected. Now dubbed Yescarta, the drug is cleared to treat adults with relapsed or refractory large B-cell lymphoma, including aggressive non-Hodgkin lymphoma, who have failed two or more traditional treatments. Source: FiercePharma 18/10/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).